Home | About PR | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |   Login 
Pharmacognosy Magazine
Search Article 
Advanced search 
Year : 2019  |  Volume : 11  |  Issue : 3  |  Page : 290-294

An open-label, multi-center, prospective, interventional, clinical study to evaluate the efficacy and safety of Ayuvigo forte capsules in patients suffering from oligospermia

1 Department of Medical Research, Target Institute of Medical Education and Research, Malad (West), Mumbai, Maharashtra, India
2 Department of Kayachikitsa, K.V.T.R. Ayurveda College, Boradi, Maharashtra, India
3 Ayurveda Research Centre, Ayurved Seva Sangh Nasik, Nashik, Maharashtra, India
4 Sunad Ayurved Center, Pune, Maharashtra, India

Correspondence Address:
Dr. Sanjay M Tamoli
Target Institute of Medical Education and Research, Ramchandra Lane Extension, Malad (West), Mumbai, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/pr.pr_158_18

Rights and Permissions

Background: Oligospermia refers to semen with a low concentration of sperms. Oligospermia is one of the common causative factors of male infertility. Objectives: The objective of this study was to assess the efficacy and safety of Ayuvigo forte capsule in patients suffering from oligospermia. Materials and Methods: This was an open-label, prospective, interventional, multi-center clinical study. A total of 30 patients were completed the study. All patients were advised to consume two Ayuvigo forte capsules twice daily orally after meals with a cup of milk for 90 days. Data describing quantitative measures are expressed as a mean ± standard deviation. Results: The mean total sperm count, mean progressive sperm motility, and total number of spermatozoa increased significantly (P < 0.05) by 90.54%, 33.65%, and 98.88% at the end of the study, respectively. Most patients had shown significant (P < 0.05) improvement in subjective parameters of low sperm count assessed as per Ayurveda. Furthermore, significant (P < 0.05) improvement was observed in mean serum free testosterone level. No statistically significant (P > 0.05) changes were observed in mean serum luteinizing hormone, follicle-stimulating hormone, prolactin, safety laboratory parameters, and vitals. Excellent overall efficacy and tolerability were observed in majority of patients. Conclusion: Ayuvigo forte capsule is safe and effective for the management of oligospermia.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded1    
    Comments [Add]    

Recommend this journal